Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session
20. November 2023 03:54 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed...
TLC Announces TLC599 Agreement with Endo
13. Juni 2022 06:30 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
07. März 2022 04:57 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas...
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain
28. Dezember 2020 04:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Reports Third Quarter 2020 Financial Results and Provides Business Update
28. Oktober 2020 04:51 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage
18. Mai 2020 02:52 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting
07. Oktober 2019 04:30 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
01. Oktober 2019 04:30 ET
|
TLC
- Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI,...
TLC Highlights Data Presentations on Lead Product Candidate TLC599 at Osteoarthritis Research Society International (OARSI) 2019 World Congress
06. Mai 2019 06:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 06, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis
15. April 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 15, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...